AI MARKET SCANNING

TG Therapeutics, Inc.

📅 Next Catalyst: Nov 02, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -2.80%
MAX GAP RECORD -42.58%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $TGTX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 02, 2026 Earnings Release 2026-11-02 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 03, 2026 Earnings Release 2026-08-03 (BEFORE OPEN)
-1.87%
May 06, 2026 Earnings Release 2026-05-06 (BEFORE OPEN)
+0.42%
Feb 26, 2026 Earnings Release 2026-02-26 (BEFORE OPEN)
-4.28%
Nov 03, 2025 Earnings Release 2025-11-03 (BEFORE OPEN)
+4.37%
Aug 04, 2025 Earnings Release 2025-08-04 (BEFORE OPEN)
-8.22%
May 06, 2025 Earnings Release 2025-05-06 (BEFORE OPEN)
-1.09%
Mar 03, 2025 Earnings Release 2025-03-03 (BEFORE OPEN)
+0.80%

VOLATILITY & GAP BIAS

AVG GAP MOVE 7.2%
Bullish Gaps (3)
Bearish Gaps (7)
Neutral / Flat (5)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $TGTX

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-29 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 1711m +15.23%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗